For the year ending 2025-12-31, VYGR had -$6,205K decrease in cash & cash equivalents over the period. -$135,063K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net (loss) income | -119,721 |
| Stock-based compensation expense | 14,787 |
| Depreciation | 4,060 |
| Amortization of premiums and discounts on marketable securities | 2,973 |
| Loss on disposal of fixed assets | -141 |
| Non-cash lease expense | 4,871 |
| Accounts receivable | 257 |
| Related party collaboration receivable | -525 |
| Prepaid expenses and other assets | -3,617 |
| Accounts payable | 1,017 |
| Accrued expenses | -2,500 |
| Operating lease liabilities | -7,227 |
| Deferred revenue | -28,807 |
| Net cash (used in) provided by operating activities | -132,467 |
| Purchases of property and equipment | 2,596 |
| Purchases of marketable securities | 133,929 |
| Proceeds from sales and maturities of marketable securities | 261,971 |
| Net cash provided by (used in) investing activities | 125,446 |
| Proceeds from the exercise of stock options | 267 |
| Proceeds from the purchase of common stock under espp | 549 |
| Net cash provided by financing activities | 816 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -6,205 |
| Cash, cash equivalents, and restricted cash beginning of period | 74,241 |
| Cash, cash equivalents, and restricted cash end of period | 68,036 |
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)